Business
FDA throws wet blanket on Mesoblast’s treatment for bone marrow transplant condition – Business News Australia
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
Before pivoting to find a treatment for critically ill COVID-19 patients suffering from severe acute respiratory distress syndrome (ARDS), Mesoblast’s (ASX: MSB, NASDAQ: MESO) most advanced business centred on an entirely different ailment.
The Melbourne-based company has sought US regulatory approval for its stem cell-based product remestemcel-L in treating graft versus host disease (GvHD) – a potentially life-threatening condition that some people experience after receiving a bone marrow tran…
-
Noosa News17 hours agoWoman was watching keepers work when lion attacked, Darling Downs Zoo says
-
Noosa News16 hours agoWorking for someone else made it hard to care for my daughter. So I quit
-
General20 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News23 hours agoTips to improve engagement – Proctor